• Home
  • About
  • All Companies
    • Recent
    • Summary Lists
  • Contact

Unravel Biosciences

  • August 13, 2021
  • New Biotech Startups

Originating from the Wyss Institute for Biologically Inspired Engineering at Harvard University, Unravel Biosciences has developed a vertically integrated computational platform to discover better drug targets.

Instead of classic pharma, which takes a target of interest and develops drugs to bind that specific target, Unravel’s platform screens many drugs in parallel for their real-world impact (e.g., the complete gene expression profiles and resulting physiological changes), reversing this process to identify the likely target(s) a drug is interacting with. Unravel’s integrated system, a combination of cell culture, a scalable CRISPR-based disease model (tadpoles), and proprietary computational software, transforms the linear process of drug discovery into an iterative loop where the outputs are continually refined.

Founded in 2021, the company is led by Richard Novak, Ph.D., a Lead Engineer at the Wyss Institute for Biologically Inspired Engineering. He is also a founder and president of the nonprofit Future Scientist and a founder and director of the sample collection technology company Rhinostics Inc.

Unravel Biosciences’ initial focus is to accelerate and de-risk the development of effective treatments for patients living with rare genetic diseases. The company also partners with discovery companies in the areas of target discovery, mechanism identification, drug optimization, and patient stratification for small molecules and biologics.


Subscribe for alerts on new companies featured on Startups.Bio


May 24, 2022Aulos Bioscience
Aulos Bioscience aims to revolutionize cancer patient care through the development of pioneering Interleukin-2 therapeutics for the treatment of solid tumor cancers. Interleukin-2 or IL-2 …
May 18, 2022Code Bio
Code Bio is using its novel targeted non-viral delivery platform to develop genetic medicines for serious and life-threatening diseases such as Type 1 Diabetes and …
May 9, 2022Muna Therapeutics
Muna Therapeutics aims to preserve brain function and enhance resilience to neurodegenerative diseases.  The company engages in the discovery and development of novel therapies that …
April 27, 2022Glyphic Biotechnologies
Glyphic Biotechnologies is an MIT spin-out aiming to accelerate the critical but slow step of sequencing new proteins, potentially cutting drug development times down by …
April 24, 2022ImmuneID 
ImmuneID is a precision immunology company that has developed a genome-wide, high-throughput platform to provide an understanding of individual immune responses. ImmuneID's aiSPIRE platform screens billions of …
April 15, 2022Flare Therapeutics
Flare uses a “switch-site based drug discovery approach” to develop a pipeline of therapeutic programs that target pivotal cancer drivers such as transcription factor dysregulation …

Tags:

© Copyright 2022. Startups.Bio, powered by VentureRadar.